BUZZ-Preview: Honeywell's post-split profit expected to decline by 62% year-on-year
路透社2026/10/21 18:51October 21 - ** Shares of Honeywell International Inc (HON.O) rose about 0.9% on Wednesday. The company is scheduled to announce quarterly earnings before the market opens on Thursday.
** According to data from London Stock Exchange Group (LSEG), the industrial conglomerate is expected to report adjusted earnings per share of $2.17 for the third quarter, a year-on-year decrease of approximately 61.6%; revenue is projected at $5.01 billion, down 51.9% from the third quarter of 2025.
** LSEG data shows that when Honeywell (HON) released its second-quarter results, its earnings per share (EPS) missed analysts’ estimates for the first time since at least the first quarter of 2021.
** On July 23, HON released its first standalone quarterly report after completing a three-way spinoff. Despite missing analysts' expectations, it raised its full-year profit forecast due to strong demand for industrial and building automation products (link).
** Of the 26 analysts covering HON, 16 rate it as “Buy” or “Strong Buy”, while the remaining 10 recommend “Hold”.
** The median 12-month price target is $262.50, down 3.5% from three months ago (LSEG).
** According to Trade Alert data, HON options imply a possible 5.0% move in the stock—up or down—by this Friday; this is lower than the stock’s average move of 5.3% on earnings days over the past eight quarters.
** So far this year, HON shares have gained 5.2%, while the Dow Jones Index .DJI is up 9.9% year-to-date.
(To assist non-English speakers, Reuters provides automated translations of its reporting into several other languages. Because automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for reader convenience. Reuters accepts no responsibility for any damages or losses arising from the use of this automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
